Press release
Cushing's Syndrome Market Outlook: Clinical Pipeline Drugs Shaping Future Therapeutic Growth and Innovation 2026
Cushing's Syndrome Market Size 2026
Cushing's syndrome market reached US$ 146.5 million in 2023 and is expected to reach US$ 291.1 million by 2031 growing with a CAGR of 8.96% during the forecast period 2024-2031.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/cushings-syndrome-market?kb
United States: Recent Industry Developments May 2026 to Jan 2026
✅ March 2026: Corcept Therapeutics Inc. expanded clinical development activities for cortisol-modulating therapies targeting patients with endogenous Cushing's syndrome.
✅ February 2026: Xeris Biopharma Holdings strengthened commercialization strategies for Recorlev® to improve treatment access for patients with hypercortisolemia associated with Cushing's syndrome.
✅ January 2026: Pfizer Inc. advanced research collaborations focused on endocrine disorder management and next-generation hormonal therapies.
✅ December 2025: Recordati Rare Diseases increased awareness initiatives and physician engagement programs supporting treatment adoption for Cushing's syndrome across the U.S. healthcare sector.
Download Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cushings-syndrome-market?kb
Cushing's Syndrome Drugs in Clinical Pipeline - Market Outlook & Key Insights
• Kettoconazole continues to be studied in clinical trials for cortisol suppression in Cushing's syndrome patients
• Levokettoconazole shows advanced pipeline potential as a steroidogenesis inhibitor for endogenous Cushing's disease
• Osilodrostat is in late-stage clinical evaluation for improved long-term cortisol control in Cushing's syndrome
• Relacorilant (glucocorticoid receptor modulator) is progressing through trials targeting hypercortisolism symptoms
• Mifepristone is under ongoing clinical research for refractory Cushing's syndrome with metabolic complications
• Osilodrostat combination therapies are being evaluated to enhance efficacy and reduce cortisol rebound effects
• Novel ACTH receptor antagonists are in early-stage pipeline development targeting pituitary-driven Cushing's disease
List of Key Players 2026:
Corcept Therapeutics, Piramal Pharma Solutions, LGM Pharma, Sigma Aldrich, Tocris Bioscience, Tecoland Corporation, Sparrow Pharmaceuticals, Novartis AG, Xeris Biopharma, and Zhejiang Supor Pharmaceuticals Co. Ltd.
Key Strategic Growth Forecast Projections 2026:
The Global Cushing's Syndrome Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: Pharmaceutical companies increased investment in rare endocrine disorder pipelines, focusing on next-generation cortisol modulators and targeted therapies for Cushing's syndrome management.
✅ April 2026: Clinical interest in Corcept Therapeutics' relacorilant expanded following positive oncology-related outcomes, strengthening broader therapeutic potential for cortisol modulation therapies.
✅ January 2026: Corcept Therapeutics continued regulatory discussions with the FDA regarding relacorilant following additional requests for efficacy data in hypercortisolism treatment applications.
✅ December 2025: The U.S. FDA issued a Complete Response Letter (CRL) for Corcept Therapeutics' relacorilant application for hypercortisolism associated with Cushing's syndrome, requesting additional evidence of effectiveness.
✅ October 2025: Regulatory momentum increased as companies advanced late-stage pipeline therapies and expanded clinical evaluation programs targeting endogenous hypercortisolism and related endocrine disorders.
✅ April 2025: Recordati received expanded FDA approval for ISTURISA® (osilodrostat) for endogenous hypercortisolemia in adults with Cushing's syndrome where surgery was not curative or feasible.
How Our Market Research Process Works:
The global Cushing's Syndrome Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Cushing's Syndrome adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• April 2026: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for approximately US$2.9 billion to strengthen its endocrinology and rare disease portfolio, including congenital adrenal hyperplasia therapies.
• January 2026: Immedica Pharma completed the acquisition of Neurocrine Group Limited from Neurocrine Biosciences for US$65 million, adding Alkindi® and Efmody® endocrine disorder treatments to its portfolio.
• January 2026: Immedica Pharma signed a definitive agreement to acquire Neurocrine Group Limited to expand into rare endocrinology and adrenal insufficiency therapies.
• April 2026: Sun Pharma signed a definitive agreement to acquire Organon in an US$11.75 billion deal, strengthening its women's health and specialty endocrinology portfolio globally.
Request Strategic Market Customization: https://datamintelligence.com/customize/cushings-syndrome-market?kb
Japan: Recent Industry Developments
✅ March 2026: Teijin Pharma expanded endocrinology-focused research activities to support improved diagnosis and management of rare hormonal disorders including Cushing's syndrome.
✅ February 2026: Takeda Pharmaceutical Company strengthened rare disease therapeutic development programs targeting endocrine and metabolic disorders.
✅ January 2026: Otsuka Pharmaceutical collaborated with healthcare institutions to improve early detection and treatment pathways for adrenal-related disorders.
✅ December 2025: Kyowa Kirin enhanced investment in specialty care and rare disease treatment innovations supporting endocrine disorder management in Japan.
Major Segments Opportunity 2026:
By Type: Endogenous Cushing's Syndrome, Exogenous/Iatrogenic Cushing's Syndrome
By Treatment: Surgery, Radiation Therapy, Drug Therapy
By End Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research & Academic Institutes
Regional Growth Intelligence for Market:
⇥ North America: 42.1% - Leads the Cushing's Syndrome market due to advanced healthcare infrastructure, strong diagnosis rates, and increasing adoption of targeted therapies.
⇥ Europe: 24.3% - Growth is driven by rising awareness, favorable reimbursement policies, and expanding endocrinology treatment access.
⇥ Asia-Pacific: 19.5% - Fastest-growing regional market supported by improving healthcare facilities and increasing endocrine disorder diagnosis rates.
⇥ Latin America: 7.2% - Market expansion is supported by growing healthcare investments and better access to rare disease treatments.
⇥ Middle East & Africa: 6.9% - Emerging growth driven by improving healthcare infrastructure and rising awareness of hormonal disorders.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=cushings-syndrome-market?kb
Market Drivers 2026:
Rapid advancements in cortisol-lowering therapies and targeted endocrine treatment approaches improving disease management and patient outcomes.
Increasing development of novel steroidogenesis inhibitors and pituitary-directed therapies expanding treatment options for Cushing's Syndrome patients.
Growing integration of artificial intelligence and digital health monitoring tools in endocrine care improving diagnosis accuracy and treatment tracking.
Expansion of clinical research activities focused on rare endocrine disorders creating new growth opportunities for pharmaceutical manufacturers.
Rising strategic collaborations among biotechnology firms, pharmaceutical companies, and research institutes to accelerate drug development and commercialization.
Continuous innovation in diagnostic assays, imaging technologies, and hormone monitoring systems enhancing clinical efficiency and patient care.
Increasing focus on rare disease awareness campaigns and early intervention programs is accelerating adoption of advanced Cushing's Syndrome treatment solutions worldwide.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cushing's Syndrome Market Outlook: Clinical Pipeline Drugs Shaping Future Therapeutic Growth and Innovation 2026 here
News-ID: 4511917 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Thin Film Batteries Market to Reach USD 1,604.50 Million by 2033 at 23.79% CAGR; …
The global thin film batteries market reached US$ 292.30 million in 2025 and is expected to reach US$ 1,604.50 million by 2033, growing at a CAGR of 23.79% during the forecast period from 2026 to 2033. The market is witnessing rapid growth driven by increasing demand for compact and flexible energy storage solutions across consumer electronics, medical devices, smart cards, wearable technologies, and Internet of Things (IoT) applications. Rising adoption…
Diabetic Neuropathy Market to Reach USD 8.40 Billion by 2033 at 6.6% CAGR; North …
The global diabetic neuropathy market reached US$ 4.47 billion in 2023, increasing to US$ 4.74 billion in 2024, and is expected to reach US$ 8.40 billion by 2033, growing at a CAGR of 6.6% during the forecast period from 2025 to 2033. The market is witnessing steady growth driven by the increasing global prevalence of diabetes, rising incidence of peripheral neuropathy complications, and growing demand for effective pain management and…
Japan Food Supplement Market by Ingredient Analysis 2026-2032 | Probiotics, Gins …
Market Growth & Size to 2031
Japan Food Supplement Market reached US$ 17,121.79 million in 2023 and is expected to reach US$ 23,486.73 million by 2031, growing with a CAGR of 8.49% during the forecast period 2024-2031.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/japan-food-supplement-market?kb
Japan: Recent Industry Developments
✅ March 2026: DHC Corporation launched advanced vitamin and mineral supplement formulations designed for active lifestyle and elderly nutrition support.
✅ February…
Why the SOC as a Service Market Is Expanding Faster Than Cybersecurity Experts E …
The global SOC as a Service market is witnessing substantial growth as enterprises increasingly adopt outsourced security operations solutions to combat rising cyber threats, ransomware attacks, and complex digital security challenges. Organizations across industries are turning to cloud-based Security Operations Center (SOC) services to improve threat detection, accelerate incident response, and reduce the operational burden of managing in-house cybersecurity infrastructure.
The growing complexity of hybrid IT environments, remote work models, and…
More Releases for Cushing
Terence Cushing Launches Personal Pledge for Proactive Legal Readiness
Image: https://www.globalnewslines.com/uploads/2026/01/1768402291.jpg
Terence Cushing, Phoenix, AZ, USA.
Terence Cushing of Phoenix, Arizona outlines a personal commitment to prevention, clarity, and responsible decision-making in today's complex legal environment.
Terence "Terry" Cushing, Senior Corporate Counsel and veteran litigation attorney, has announced the launch of a new personal pledge focused on proactive legal readiness, clear communication, and early risk awareness. The pledge reflects lessons drawn from nearly two decades in federal courts, private practice, and corporate…
Cushing Syndrome Clinical Trial Pipeline Shows Potential with Active Contributio …
DelveInsight's "Cushing Syndrome Pipeline Insight 2026" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Cushing Syndrome Market Is Going to Boom | Major Giants HRA Pharma • Recordati …
Coherent Market Insights has released a report titled "Cushing Syndrome Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribution, and growth potential. This comprehensive report encompasses industry performance, critical success factors, risk assessment, manufacturing prerequisites, project expenses, economic analysis, anticipated return on investment (ROI), and profit margins.
➤ Christmas Exclusive Deal…
Cushing Syndrome Market Trends is Electrifying Growth Cycle: Bristol Myers Squib …
The latest study released on the Global Cushing Syndrome Market by HTF MI Research evaluates market size, trend, and forecast to 2031. The Cushing Syndrome market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players…
Cushing Syndrome Pipeline Appears Robust With 4+ Key Pharma Companies Actively W …
DelveInsight's, "Cushing Syndrome Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Cushing Syndrome…
Cushing Syndrome Market Is Booming So Rapidly | Recordati, Diurnal Group, Pfizer
The Global Cushing Syndrome Market Size is estimated at $1.4 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 22.6% to reach $8.8 Billion by 2034.
The latest study released on the Global Cushing Syndrome Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Cushing Syndrome market study covers significant research data and proofs to be a handy resource document for…
